Rocket Pharmaceuticals, Inc. Impairment of Long-Lived Assets Held-for-use
Rocket Pharmaceuticals, Inc. (RCKT) reported Impairment of Long-Lived Assets Held-for-use of $600.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2025-02-27
- Rocket Pharmaceuticals, Inc. impairment of long-lived assets held-for-use for the quarter ending 2020-12-31 was -$62.00K.
- Rocket Pharmaceuticals, Inc. impairment of long-lived assets held-for-use for the quarter ending 2020-09-30 was $0.00.
- Rocket Pharmaceuticals, Inc. impairment of long-lived assets held-for-use for the quarter ending 2020-06-30 was -$1.00K.
- Rocket Pharmaceuticals, Inc. impairment of long-lived assets held-for-use for the quarter ending 2020-03-31 was $63.00K.
- Rocket Pharmaceuticals, Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $600.00K.
- Rocket Pharmaceuticals, Inc. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- Rocket Pharmaceuticals, Inc. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
- Rocket Pharmaceuticals, Inc. impairment of long-lived assets held-for-use for fiscal 2020 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month | Impairment of Long-Lived Assets Held-for-use 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | $600.00K 10-K · filed 2025-02-27 | ||||
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | ||||
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 | ||||
| 2020-12-31 | -$62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$62.00K derived: sum of 2 quarters · filed 2023-02-28 | -$63.00K derived: sum of 3 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$1.00K derived: sum of 2 quarters · filed 2020-11-06 | $62.00K 10-Q · filed 2020-11-06 | $62.00K derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $62.00K 10-Q · filed 2020-08-05 | $62.00K derived: sum of 3 quarters · filed 2022-02-28 | $62.00K derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | $63.00K 10-Q · filed 2020-05-08 | $63.00K derived: sum of 2 quarters · filed 2022-02-28 | $63.00K derived: sum of 3 quarters · filed 2022-02-28 | $63.00K derived: sum of 4 quarters · filed 2022-02-28 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $0.00 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-08 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 | ||||
| 2017-12-31 | -$217.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | -$217.00K derived: sum of 2 quarters · filed 2019-03-08 | $0.00 derived: sum of 3 quarters · filed 2019-03-08 | $0.00 10-K · filed 2019-03-08 | $217.00K 10-K · filed 2018-03-07 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $217.00K derived: sum of 2 quarters · filed 2017-11-08 | $217.00K 10-Q · filed 2017-11-08 | ||
| 2017-06-30 | $217.00K 10-Q · filed 2017-08-03 | $217.00K 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | $217.00K 10-Q · filed 2017-05-10 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |